Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations

INTRODUCTION: The effect of disease-modifying therapies (DMT) on vaccine responses is largely unknown. Understanding the development of protective immunity is of paramount importance to fight the COVID-19 pandemic. OBJECTIVE: To characterise humoral immunity after mRNA-COVID-19 vaccination of people...

Descripción completa

Detalles Bibliográficos
Autores principales: König, Marton, Lorentzen, Åslaug Rudjord, Torgauten, Hilde Marie, Tran, The Trung, Schikora-Rustad, Stine, Vaage, Eline Benno, Mygland, Åse, Wergeland, Stig, Aarseth, Jan, Aaberge, Ingeborg Aase S, Torkildsen, Øivind, Holmøy, Trygve, Berge, Tone, Myhr, Kjell-Morten, Harbo, Hanne Flinstad, Andersen, Jan Terje, Munthe, Ludvig Andre, Søraas, Arne, Celius, Elisabeth Gulowsen, Vaage, John Torgils, Lund-Johansen, Fridtjof, Nygaard, Gro Owren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763174/
https://www.ncbi.nlm.nih.gov/pubmed/34670844
http://dx.doi.org/10.1136/jnnp-2021-327612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763174/
https://www.ncbi.nlm.nih.gov/pubmed/34670844
http://dx.doi.org/10.1136/jnnp-2021-327612

Ejemplares similares